Welcome!

News Feed Item

Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid

NEW BRUNSWICK, N.J., Sept. 4, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak.

The accelerated vaccine program features a prime-boost regimen, in which one vector is used to prime and the other to boost the immune response.  It consists of two vaccine components that are based on AdVac® technology from Crucell N.V. (part of the Janssen pharmaceutical companies of Johnson & Johnson, based in the Netherlands) and the MVA-BN® technology from Bavarian Nordic, (a biotech company, based in Denmark).  The program has received direct funding and is also utilizing vaccine preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of National Institutes of Health (NIH). Crucell will bring this development program forward, in close collaboration with Bavarian Nordic and the NIAID, to allow for initiation of a clinical trial of this combined regimen in humans in early 2015.

The company's expedited vaccine development schedule is in response to the current Ebola outbreak in West Africa and is aligned with the World Health Organization's Ebola Response Roadmap, including its call to fast-track access to treatment and vaccine options to address the Ebola virus outbreak.

Johnson & Johnson's multi-pronged approach, as part of their overall commitment to prevent disease in vulnerable populations, includes:

  • an intensive review of known pathways in Ebola pathophysiology to determine whether previously tested medicines can be used to help patients survive an Ebola infection, and
  • additional support to the non-profit organization Direct Relief International to facilitate the air transport of a variety of infection prevention products to Liberia and Sierra Leone.

"Patients are at the heart of everything we do.  Our primary goal in this escalating Ebola epidemic is to assist governments in protecting health care workers, families and populations who are at high risk of being infected with Ebola as soon as possible in an effort to stop the disease from spreading further," said Paul Stoffels, M.D., Chief Scientific Officer of Johnson & Johnson.  "With a strong heritage in collaborative partnerships and a proven track record in the rapid development and access of innovative products, we aim to ultimately eradicate deadly diseases like Ebola and save lives around the world."

Crucell and Bavarian Nordic are both currently developing preventive vaccines against filoviruses, including Ebola virus, with direct funding and vaccine preclinical services from NIAID.  In addition, the two companies have developed a combination regimen that harnesses the potency of both vaccines and could be used to elicit protective immunity against the Zaïre species of the Ebola virus, which is responsible for the current outbreak in West Africa.  The combination vaccine provided complete protection of vaccinated macaques against disease and death after exposure to a highly virulent wildtype Ebola Zaire strain. 

Based on these promising results, Bavarian Nordic, Crucell and NIAID intend to advance this development program to allow for initiation of a human trial in early 2015. 

The combination regimen uses proven vaccine technology platforms from both companies that have shown to be immunogenic and safe when used in humans for other applications:  to date more than 1,000 humans have received Crucell's adeno-platform based vaccine in clinical trials, while Bavarian Nordic's MVA-BN platform is the basis of the smallpox vaccine registered in Canada and Europe and stockpiled in the rest of the world with a safety record of use in more than 7,300 humans.  In addition to the clinical advantage of the combination regimen, the collaboration also allows for faster production with each company taking on the production of one element of the combination regimen.

Crucell has been exploring vaccines as well as other related programs targeting diseases with potential widespread social impact in partnership with the NIH since 2002.  This new research collaboration for a monovalent vaccine targeting the Zaire strain of the Ebola virus is part of an ongoing development program for a multivalent vaccine against all filoviruses that cause disease in humans, including Ebola and Marburg viruses.

"In light of the current emergency in West Africa and given the evident, huge unmet medical need, we are stepping up our efforts and accelerating the Ebola program currently in pre-clinical development," said Johan Van Hoof, M.D., Global Head, Infectious Diseases and Vaccines, Janssen and Managing Director, Crucell.  "We recognize the urgency of the situation and the need to collaborate with multiple partners to develop treatment and preventive solutions for Ebola."

The emergence of Ebola in West Africa has also strained the health care systems of Liberia, Sierra Leone and Guinea. The company's long tradition of disaster response has prompted support of Direct Relief International's efforts in this area.  Johnson & Johnson is also participating in the ongoing efforts by public health authorities, including the Centres for Disease Control and the WHO, to mount a coordinated world response to address the immediate needs raised by the Ebola outbreaks.

About Ebola

The Ebola virus belongs to a virus family called Filoviridae and can cause severe hemorrhagic fever in humans and nonhuman primates.  Ebola has a mortality rate ranging from 50% to 90% according to the World Health Organization.  The virus is highly prioritized by the U.S. Government, who has defined the virus as a "Category A" agent, due to its high mortality rate.  Currently, no licensed vaccine, treatment or cure exists for this disease.

About Johnson & Johnson

Caring for the world one person at a time inspires and unites the people of Johnson & Johnson.  We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About Crucell

Crucell is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and is focused on research development and production of vaccines, proteins and antibodies that prevent and/or treat infectious diseases.  Crucell is a major supplier of vaccines to UNICEF and the developing world.  Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine named Quinvaxem®.  With this innovation, Crucell has become a major partner in protecting children in developing countries against major infectious diseases.  Crucell has a broad development pipeline, with several product candidates based on its unique AdVac® and/or PER.C6® production technology.  Crucell licenses its PER.C6® technology and other technologies to the biopharmaceutical industry.

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases.  Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. 

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Crucell N.V. and/or Johnson & Johnson.

Risks and uncertainties include, but are not limited to, challenges and uncertainties inherent in product development, including the timeline for the potential availability of a vaccine against Ebola.

A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.)

SOURCE Johnson & Johnson

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Outscale, a global pure play Infrastructure as a Service provider and strategic partner of Dassault Systèmes, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2010, Outscale simplifies infrastructure complexities and boosts the business agility of its customers. Outscale delivers a secure, reliable and industrial strength solution for its customers, which in...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 20th Cloud Expo, Tom Eck, Industry Platforms CTO at IBM Cloud, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing developers ...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
In his session at 20th Cloud Expo, Brad Winett, Senior Technologist for DDN Storage, will present several current, end-user environments that are using object storage at scale for cloud deployments including private cloud and cloud providers. Details on the top considerations of features and functions for selecting object storage will be included. Brad will also touch on recent developments in tiering technologies that deliver single solution and an end-user view of data across files and objects...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, w...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assis...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
As cloud adoption continues to transform business, today's global enterprises are challenged with managing a growing amount of information living outside of the data center. The rapid adoption of IoT and increasingly mobile workforce are exacerbating the problem. Ensuring secure data sharing and efficient backup poses capacity and bandwidth considerations as well as policy and regulatory compliance issues.
Interested in leveling up on your Cloud Foundry skills? Join IBM for Cloud Foundry Days on June 7 at Cloud Expo New York at the Javits Center in New York City. Cloud Foundry Days is a free half day educational conference and networking event. Come find out why Cloud Foundry is the industry's fastest-growing and most adopted cloud application platform.